214470-61-8

Basic information

• Product Name: 7-(2-chloroethoxy)-4-hydroxy-6-methoxyquinoline-3-carbonitrile
• Synonyms: 7-(2-Chlorethoxy)-4-hydroxy-6-methoxychinolin-3-carbonitril
• CAS NO: 214470-61-8
• Molecular Formula: C₁₃H₁₁ClN₂O₃
• Molecular Weight: 278.691
• Mol File: 214470-61-8.mol

Chemical Properties

• Boiling Point: 487°C at 760 mmHg
• Flash Point: 248.4°C
• Density: 1.41g/cm³
• Vapor Pressure: 4.13E-10mmHg at 25°C
• Refractive Index: 1.635
• CAS DataBase Reference: 7-(2-chloroethoxy)-4-hydroxy-6-methoxyquinoline-3-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(2-chloroethoxy)-4-hydroxy-6-methoxyquinoline-3-carbonitrile(214470-61-8)
• EPA Substance Registry System: 7-(2-chloroethoxy)-4-hydroxy-6-methoxyquinoline-3-carbonitrile(214470-61-8)

Safety Data

• Hazardous Substances Data: 214470-61-8(Hazardous Substances Data)

Upstream product

• 20428-58-4 α-lithioacetonitrile 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 75-05-8 acetonitrile 
• 214470-60-7 2-amino-4-(2-chloroethoxy)-5-methoxybenzoic acid methyl ester 
• 214470-58-3 4-(2-chloroethoxy)-5-methoxy-2-nitrobenzoic acid methyl ester 
• 214470-56-1 4-(2-Chloro-ethoxy)-5-methoxy-benzoic acid methyl ester 
• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 

Downstream Products

• 214470-72-1 4-chloro-7-(2-chloroethoxy)-6-methoxy-3-quinolinecarbonitrile 
• 863029-96-3 7-(2-chloroethoxy)-6-methoxy-4-(4-phenoxyphenylamino)quinoline-3-carbonitrile 

Relevant articles and documents

USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula (1); wherein R1, R2, R3, R4, X, Y, and n are defined hereinbefore, or a pharmaceutically acceptable salt thereof.

SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS

This invention provides compounds of formula (1) wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

SUBSTITUTED 3-CYANO QUINOLINES

This invention provides compounds having formula (1), wherein: X is cycloalkyl which may be optionally substituted; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally substituted; n is 0-1; Y is -NH-, -O-, -S-, or -NR-; R is alkyl of 1-6 carbon atoms; R1, R2, R3 and R4 are each, independently, hydrogen, halogen, alkyl, alkenyl, alkynyl, alkenyloxy, alkynyloxy, hydroxymethyl, halomethyl, alkanoyloxy, alkenoyloxy, alkynoyloxy, alkanoyloxymethyl, alkenoyloxymethyl, alkynoyloxymethyl, alkoxymethyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulfonamido, alkenylsulfonamido, alkynylsulfonamido, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy, carboalkyl, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino, alkylamino, dialkylamino, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, phenylamino, benzylamino, formulae (a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p, q or r); R5 is alkyl which may be optionally substituted, or phenyl which may be optionally substituted; R6 is hydrogen, alkyl, or alkenyl; R7 is chloro or bromo; R8 is hydrogen, alkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-cycloalkylaminoalkyl, N-cycloalkyl-N-alkylaminoalkyl, N,N-dicycloalkylaminoalkyl, morpholino-N-alkyl, piperidino-N-alkyl, N-alkyl-piperidino-N-alkyl, azacycloalkyl-N-alkyl, hydroxyalkyl, alkoxyalkyl, carboxy, carboalkoxy, phenyl, carboalkyl +, chloro, fluoro, or bromo; Z is amino, hydroxy, alkoxy, alkylamino, dialkylamino, morpholino, piperazino, N-alkylpiperazino, or pyrrolidino; m = 1-4, q = 1-3, and p = 0-3; any of the substituents R1, R2, R3 or R4 that are located on contiguous carbon atoms can together be the divalent radical -O-C(R8)2-O-; or a pharmaceutically acceptable salt thereof with the proviso that when Y is -NH-, R1, R2, R3 and R4 are hydrogen, and n is O, X is not 2-methylphenyl, which are inhibitors of protein tyrosine kinase.

Method of treating or inhibiting colonic polyps

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula 1 wherein:R1, R2, R3, R4, X, Y, and n are as defined hereinbefore, or a pharmaceutically acceptable salt thereof.

Synthesis and structure-activity relationships of 3-cyano-4(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors

A series of 3-cyano-4-(phenoxyanilino)cyanoquinolines has been prepared as MEK (MAP kinase kinase) inhibitors. The best activity is seen with alkoxy groups at both the 6- and 7-positions. The lead compounds show low nanomolar IC50's against MAP kinase kinase, and have potent inhibitory activity in tumor cells. (C) 2000 Elsevier Science Ltd.